Dr. Andrew Glass served as research director of Northwest Permanente, KPNW’s physician group, from 1985 until 1997. In this capacity, he acted as a liaison to CHR for studies initiated and conducted by Northwest Permanente physicians. He also served as chief of medical oncology for KPNW.
His principal interests include breast cancer research and cancer prevention, with a focus on exploiting Kaiser Permanente's considerable tissue and medical resources and making them available to university investigators for studies of prognostic and predictive tumor markers.
Dr. Glass served on Oregon's Health Services Commission for 10 years, including six years as chair, and was a member of the Commission on Cancer for the American College of Surgeons. He is a clinical professor in public health and preventive medicine at Oregon Health & Science University.
Dr. Glass received his MD from the University of Pennsylvania.
Selected Publications
- Nyante SJ, Sherman ME, Pfeiffer RM, Berrington de Gonzalez A, Brinton LA, Aiello Bowles EJ, Hoover RN, Glass A, Gierach GL. Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer. JNCI National Cancer Inst 2015;107(3) [Epub 6 Feb 2015]
- Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Richhariya A, Dodge T, Wolff GG, Balakumaran A, Edelsberg J. Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer. 2014 May;22(5):1363-73. doi: 10.1007/s00520-013-2094-y. Epub 2014 Jan 4.
- Rohan T, Xue X, Lin HM, D'Alfonso TM, Ginter PS, Oktay MH, Robinson BD, Ginsberg M, Gertler FB, Glass AG, Sparano JA, Condeelis JS, Jones J. Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. J Natl Cancer Inst. 2014 Jun 3;106(8). pii: dju136. doi: 10.1093/jnci/dju136. Print 2014 Aug.
- Weyker D, Barron R, Edelsberg J, Kartashov A, Legg, J, and Glass A. Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis. BMC Health Services Research. 2014, 14:189. DOI: 10.1186/1472-6963-14-189.
- Kamineni A, Weinmann S, Shy KK, Glass AG, Weis NS. Efficacy of screening in preventing cervical cancer among older women. Cancer Causes Control. 2013 Sep; 24(9):1653-60. doi: 10.1007/s10552-013-0239-4. [Epub 2013 Jun 7]